<DOC>
	<DOCNO>NCT01084538</DOCNO>
	<brief_summary>This post-marketing study conduct two country : Croatia Serbia . In country Zemplar ( paricalcitol ) first injectable form Vitamin D Receptor ( VDR ) activator available chronic kidney disease patient hemodialysis . The evaluation outcomes VDR activator treatment clinical practice major challenge management patient population . The aim post-marketing observational study obtain data outcome Zemplar Injection administration routine clinical use .</brief_summary>
	<brief_title>Study Zemplar iv Patients With End Stage Chronic Kidney Disease , Undergoing Haemodialysis</brief_title>
	<detailed_description>This study non-interventional , observational study Zemplar® Injection prescribe usual manner accordance term local Summary Product Characteristics ( SmPC ) regard dose , population indication . The study population consist participant receive hemodialysis diagnosis secondary hyperparathyroidism establish , adequately control oral VDR activator ( calcitriol alfacalcidol ) . Participants include via consecutive sampling . To include , participant clinical indication initiate treatment Zemplar® Injection due : ( 1 ) diagnosis secondary hyperparathyroidism ( 2 ) require change treatment secondary hyperparathyroidism ( e.g . due lack effectiveness previous treatment ) . Each participant observe his/her Zemplar® Injection treatment regimen maximum period 12 month .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Subject 18 year age diagnose secondary hyperparathyroidism pretreatment iPTH &gt; 300 pg/mL , receive chronic hemodialysis . Subject treatment Zemplar Injection indicate clinically accord criterion participate investigator . Subject correct serum calcium &gt; 10.5 mg/dL , serum phosphorus &gt; 6.5 mg/dL subject correct Ca x P &gt; 65 . Subject know hypersensitivity and/or toxicity vitamin D metabolites and/or product ingredient , participate clinical study within last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>paricalcitol iv</keyword>
	<keyword>vitamin D</keyword>
	<keyword>secondary hyperparathyroidism</keyword>
	<keyword>hemodialysis</keyword>
</DOC>